News First biosimilar fast-acting insulin reaches US market Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog.
News Small study finds GLP-1 drug can curb excess alcohol use Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.
News Pharma group slams Hims & Hers over Super Bowl GLP-1 ad Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."
News Novo charts course ahead for CagriSema after lacklustre data After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.
News Novo rises on Wegovy sales leap, but warns of a slowdown Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.
News Ozempic is first GLP-1 drug FDA-approved for kidney disease Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
